Table 2.

Guideline recommendations [according to (2, 26, 27).

Clinical situation	Recommendation	Treatment duration
Asymptomatic PAD without other clinical manifestations of atherosclerosis	No antiplatelet therapy	Since clinical situation changes (for example newly diagnosed cardiovascular disease)
Symptomatic PAD and low bleeding risk	Rivaroxaban 2.5 mg b.d. and ASA 100 mg o.d.	Long-term, regular assessment of bleeding risk
Symptomatic PAD and high bleeding risk	Clopidogrel 75 mg o.d. or alternatively ASA 100 mg o.d.	Long-term
After endovascular revascularization and low bleeding risk	Rivaroxaban 2.5 mg b.d. and ASA 100 mg o.d.	Long-term, if temporary addition of clopidogrel 75 mg duration shout be less than 30 days
After endovascular revascularization and high bleeding risk	Clopidogrel 75 mg o.d. or alternatively ASA 100 mg o.d.	Long-term, if temporary addition of clopidogrel as short as possible
After surgical revascularization and low bleeding risk*	Rivaroxaban 2.5 mg b.d. and ASA 100 mg o.d.	Long-term, regular assessment of bleeding risk
After surgical revascularization and high bleeding risk*	Clopidogrel 75 mg o.d. or alternatively ASA 100 mg o.d.	Long-term
PAD patients with indication for anticoagulation	Anticoagulation only	Long-term

^*In some cases VKA can be discussed after venous grafts and ASA plus Clopidogrel after prosthetic grafts.

o.d.,omne in die, once daily; b.d., bis in die, twice daily.